The Food and Drug Administration has created new information sites about Postmarket Drug Safety Information for Patients and Providers. As a service, we will keep this link live on our home pages.
In accordance with Section 915 of the Food and Drug Administration Amendments Act of 2007 (FDAAA), this website contains links to postmarket drug safety information to improve transparency and communication to patients and health care providers.
Drug Labeling- Approved Professional, Patient Labeling, and Patient Package Inserts in Drugs@FDA
- DailyMed Drug labeling on this Web site is the most recent submitted to FDA and currently in use; it may include, for example, strengthened warnings undergoing FDA review or minor editorial changes.
- List of Products with Medication Guides
- List of REMS
- Federal Register Notice: Identification of Drug and Biological Products Deemed to Have Risk Evaluation and Mitigation Strategies for Purposes of the Food and Drug Administration Amendments Act of 2007.
- Postmarket Study Requirements and Commitments Searchable database of CDER and CBER commitments.
- Clinicaltrial.gov Registry and Results Databank ClinicalTrials.gov is a registry of federally and privately supported clinical trials conducted in the United States and around the world. These trials are designed primarily to evaluate the premarket efficacy and safety of drugs and biologics, as well as for new indications for products currently marketed.
- Index to Drug-Specific Information For patients, consumers, and health care professionals, provides links to safety sheets with the latest risk information about particular drugs, related press announcements, and other fact sheets.
- CDER What's New web page Includes drug safety announcements from CDER and MedWatch.
- Medical Product Safety Information from MedWatch
- FDA Drug Safety Podcasts Provides emerging safety information about particular drugs in conjunction with the release of Public Health Advisories.
- Drug Safety Newsletter This publication provides postmarket information to health care professionals to enhance communication of new drug safety information, raise awareness of reported adverse events, and stimulate additional adverse event reporting.
- Potential Signals of Serious Risks/New Safety Information Identified by the Adverse Event Reporting System (AERS)
- AERS Quarterly Data Files Access to the raw data extracted from the AERS database.
- Code of Federal Regulations, Title 21 - Food and Drugs Many FDA regulations related directly or indirectly to safety
- Selected Safety Regulations
- FDA Guidance Documents Many guidances relate to safety
- CDER Guidances on Drug Safety
- Guidance: Drug Safety Information - FDA's Communication to the Public
- Notice of Availability [TXT] [PDF]
- Find the Latest Drug Product and Safety Information
- A Guide to Drug Safety Terms at FDA
- Spotlight On...Strengthening Drug Safety
- Consumer Update: Managing Drug Safety Issues - Questions and Answers with Paul Seligman, M.D., M.P.H
- Keeping Up With Drug Safety Information
- MedlinePlus Authoritative drug and health information from the National Institutes of Health (NIH), and other government agencies and health-related organizations.
- FDA News: FDA Reinforces Commitment to Drug Safety
- The Future of Drug Safety - Promoting and Protecting the Health of the Public
